RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA MARKET ANALYSIS

Market Challenges And Opportunities

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market– Drivers

• Increasing incidence rate of R/R DLBCL: Diffuse large B cell lymphoma (DLBCL) is the most common type of non hodgkins lymphoma (NHL) that accounts forapproximately 31% of all NHL in Western countries and 37% of B-cell tumors worldwide. The median age at presentation is 66, however, DLBCL can occur at any age. There is a slightly higher incidence in men (6.7 vs 4.6 cases per 100,000 persons, male vs female). The probability of having DLBCL increases with age, from 0.13% and 0.09% before the age of 39 to 1.77% and 1.4% after the age of 70 in men and women, respectively. 5-year survival rates decrease by age from 78% for those aged <55 years to 54% for those aged ≥ 65 years.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market– Restraints

• Treatment challenges for the geriatric patient group: Geriatric patients have decreased tolerance of chemotherapy because of limited bone marrow reserve, altered drug metabolism, presence of comorbid conditions, or impaired physical function and/or cognition. Resulting concerns may lead to application of attenuated regimens or withholding curative therapy based on age alone, which may not always be well-justified clinically.
• Counterbalance: Key players are focusing on developing advanced products with safety and cost effective for geriatric patient